Lowest Price Guaranteed
Pages
195
Last Updated
May 2025
View Count
5747
The global bioprocess analyzers market, valued at USD 2.58 billion in 2024, is projected to reach USD 2.88 billion in 2025 and USD 7.23 billion by 2035, representing a CAGR of 9.6% during the forecast period.
 |
To learn more about this report, request a free sample copy
Bioprocess analyzer refers to the specialized instrument that is used to analyze and monitor numerous parameters within biological processes, such as cell growth, substrate level, and metabolite concentration. The information about biological processes helps pharmaceutical companies to control and optimize the production of desired therapeutics.
Bioprocess analyzers are gaining traction driven by the growing research on advanced pharmaceutical products to treat chronic conditions. As per the statistics published by Centers for Disease Control and Prevention in July 2024, around 1.7 million people in United States are diagnosed with cancer and over 9,44,800 Americans die due to heart diseases every year. Notably, the cardiovascular diseases are estimated to cost the US healthcare system USD 2 trillion by 2050. In order to mitigate the growing concern of diseases, pharmaceutical industry is focusing on the development of advanced therapies by using monoclonal antibodies, bispecific antibodies and other biologics.
However, it is worth mentioning that biology is highly complex and sensitive, it requires highly controlled conditions for precise manufacturing. These bioprocess analyzers help to monitor cellular processes in real-time, allowing manufacturers to adjust the parameters for maximum yield without wastage.
Considering the ongoing demand, several industry players are increasingly focusing on the development of advanced bioprocess analyzer instruments. For instance, in August 2024, Eppendorf announced launching of BioNsight cloud software solution for bioprocess monitoring and analysis. This advance software solution makes it easier to analyze and consolidate bioprocess data in once central locations. Furthermore, in March 2025, Repligen (a life sciences company focused on bioprocessing technology) announced that the company has purchased 908 Devices desktop portfolio of four devices for bioprocessing process analytical technology applications.
Owing to the increasing initiatives by industrial players, we believe that bioprocess analyzer market is expected to grow at a steady rate during the forecast period.
The market research report presents an in-depth analysis of companies that are involved in the global bioprocess analyzers industry, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2020 | |
| Forecast Period | Till 2035 | |
| Market Size 2025 | USD 2.88 Billion | |
| Market Size 2035 | USD 7.23 Billion | |
| CAGR (Till 2035) | 9.6% | |
| Type of Product |
|
|
| Type of Analysis |
|
|
| Type of Modality |
|
|
| Application Area |
|
|
| End User |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled | (A complete list of companies captured is available in the report) | |
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of the bioprocess analyzers market report was to estimate the current size, opportunity, and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.
The global market analysis report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of product (instruments and consumables & accessories), type of analysis (substrate analysis, metabolite analysis and concentration detection), type of modality (bench-top biochemistry analyzer and floor-standing analyzer), application area (antibiotics, recombinant proteins, biosimilars and other applications), end users (biopharmaceutical companies, CROs & CMOs, research & academic institutes and other end users), geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America) and leading players.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three bioprocess analyzers market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.
Based on the type of product, the global market is segmented into instruments (spectrometers, chromatographs, pH Or DO analyzers, gas analyzers, flow cytometers and offline analyzers) and consumables & accessories (reagents, sensors, calibration kits, culture media and filters). According to our bioprocess analyzers market forecast, presently consumables & accessories segment accounts for the largest share (55%) of the market. This can be attributed to the rising demand for consumables for continuous bioprocessing technologies. Consumables, such as sensors, filters and calibration kits when combined with bioprocessing technology help to enhance processing efficiency with higher efficacy rate. Additionally, the increasing demand for advanced consumables for automated sample systems and bioprocess analyzers are further contributing to the highest CAGR of this segment during the forecast period.
In addition, instruments such as flow cytometers and spectrometers find their applications in bioprocess monitoring and analysis.
This segment highlight the distribution of global market across different type of analysis, such as substrate analysis, metabolite analysis and concentration detection. According to our bioprocess analyzers market report, currently, the concentration detection segment holds more than 50% share of the market. This can be attributed to the heightened demand for bioprocess analyzers for the detection of biologics concentration.
During biologics production, it is essential to measure dissolved oxygen concentration, proteins, pH levels and cell densities to ensure higher product consistency. Considering the demand, this segment is likely to remain dominant and is poised to grow at a higher CAGR during the forecast period.
Based on the type of modality, the global market is segmented into bench-top biochemistry analyzer and floor-standing analyzer. According to our bioprocess analyzers market analysis, currently, bench-top biochemistry analyzer holds the highest share (nearly 75%) of the market. This can be attributed to the fact that bench-top biochemistry analyzers are highly compact in size and offer higher versatility to analyze cell cultures.
Moreover, it also allows us to perform numerous biochemical tests and handle a wide array of assays. Additionally, the increasing preferences for point of care diagnostics has further driven the demand for bench-top analyzers. Driven by the going preferences, this segment will continue to grow at a higher CAGR during the forecast period.
The global market is distributed across different application areas, such as antibiotics, recombinant proteins, biosimilars and other applications. According to our global bioprocess analyzers market, currently, the antibiotics segment accounts for the highest share (over 30%) of the market. This can be attributed to the increasing demand for monoclonal antibodies for the treatment of cancer and other chronic conditions. Antibodies require a controlled processing environment due to complex microbial fermentation.
Real-time bioprocess analyzer solutions for continuous fermentation monitoring are essential in this context, as bioprocess analyzers come with advanced sensors that enable real-time analysis of deviation in fermentation environment. It is important to highlight here that driven by the growing demand for bioprocess analyzers for antibiotics product, this segment will continue to grow at a higher CAGR during the forecast period.
Based on the end user, the global market is segmented into biopharmaceutical companies, CROs & CMOs, research & academic institutes and other end users. According to our market report, currently the biopharmaceutical companies sub-segment is holding more than 45% share of bioprocess analyzers industry. This can be attributed to the growing focus on biologics for the treatment of wide range of diseases. Biologics require specialized processing conditions and bioprocess analyzers play a significant role in maintaining controlled conditions, which is likely to be a key reason for higher adoption of this technology in biopharmaceutical companies.
However, in the long run, CROs and CMOs segment is expected to register a higher CAGR during the forecast period. This can be attributed to the growing shift towards biologics contract manufacturing.
Based on the type of geographical region, the global market is distributed across North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our market forecast, currently North America holds the highest bioprocess analyzers market share (40%). This can be attributed to the growing demand for advanced biologics based drugs to treat chronic conditions. Additionally, the increasing expansion of bioprocessing manufacturing to meet the growing demand for personalized therapeutics has further necessitated the requirement for bioprocess analyzers.
However, in Asia-Pacific, the market for bioprocess analyzers is likely to grow at a higher CAGR during the forecast period. This is likely to be the result of increasing demand for advanced sensors based analyzing technologies by pharmaceutical industries to support the manufacturing of biologics in this region. Additionally, stringent guidelines and good manufacturing practices protocol has further underscored the requirement of bioprocess analyzers.
The “Bioprocess Analyzers Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities for bioprocess analyzer companies. Key takeaways of the market report are briefly discussed below.
According to our analysis, the current market landscape is highly competitive, witnessing the presence of wide array of well-established and new entrants. The primary focus of industrial players is on automation and technological innovations to facilitate real-time data analysis.
Market players such as Agilent Technologies, BD and Danaher are expanding their production portfolio to strengthen their position in the market. In order to leverage competitive edge, several industrial players are also focusing on collaborations and partnerships. For instance, in June 2024, Genedata and AGU entered into a strategic partnership to provide a fully integrated and comprehensive laboratory digitalization solution to automate the bioprocess development workflows. This fully integrated digitalization solution helps to collect data from bioprocess analyzer instruments and streamline the information flow into Genedata enterprise platform for analysis.
As more market players continue to accelerate their innovations, we believe that the market will remain competitive during the forecast period.
The market for bioprocess analyzers is expected to be driven by the increasing biopharmaceutical production and expanding R&D activities on advanced drugs. Notably, biopharmaceutical drugs or bioactive drugs are derived from living cells or their components. These bioactive drugs require specialized manufacturing conditions to maintain the drug efficacy and wastage, which necessitated the demand for bioprocess analyzers for real-time monitoring. In addition, the rising research and development activities on diseases and drugs further underscore the requirement of bioprocess analyzers.
Several factors that may impede the market growth includes stringent guidelines and high cost of bioprocess analyzer instruments and maintenance. It is worth mentioning that market players are required to meet with complex guidelines associated with the use of technologies for the manufacturing of biopharmaceuticals. These complex guidelines may delay the process of development and commercialization of bioprocess analyzers. Additionally, the high cost of bioprocess analyzer instruments and reagents may create hindrance in the adoption on a large scale.
Despite of challenges, the market landscape is witnessing an upward trajectory driven by the increasing technological advancements and automation. Currently, the market players are focusing on the automated bioprocess analyzer for cell culture optimization in biotechnology and integration of advanced technologies specifically biosensors for real-time analysis of specific concentration of biologics. In addition, the growing focus on the single use systems, Raman Spectroscopy and shift towards advanced data acquisition tools for time real-time adjustment during bioprocessing for maintaining product quality is driving growth in this market.
Currently, the global market for bioprocess analyzers is estimated to be valued at USD 2.88 billion in 2025 and is projected to reach USD 7.23 billion by 2035, representing a CAGR of 9.6% during the forecast period. The global market is expected to be driven by the growing focus on biologics based drugs to treat chronic conditions and heightened demand for control bioprocess manufacturing.
In order to meet the growing demand, several industrial players are focusing on investments and collaborations. In December 2024, Abselion (UK based company) raised £6.6 million in Series A funding round led by M Ventures along with other participants from investors BioProcess 360 Partners and Untiled Ventures and other existing investors. The company will utilize these funds in streamlining and accelerating access to the redox-electrochemical-detection (RED) technology and at-line protein analytics for the development of biologics, such as antibiotics. These instruments will allow scientists in quantification of antibodies, proteins and AAV Vector directly from the crude samples in less than one minute.
Examples of key players engaged in this domain (which have also been captured in this report) include Agilent Technologies, BD, Beckman Coulter, Bio-Rad Laboratories, Bruker, BioTek Instruments, Biochrom, Danaher, Eppendorf, Gilson, HORIBA, Hamilton, Merck, Metrohm, MilliporeSigma, Macherey-Nagel, Nova Biomedical, Promega, PerkinElmer, Sartorius, Thermo Fisher Scientific and Zymo Research. This market report includes an easily searchable excel database of all the companies focusing on the development of bioprocess analyzers.
The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this domain across different segments. Amongst other elements, the market report includes:
Several recent developments have taken place in the field of bioprocess analyzer. We have outlined some of these recent initiatives below.